Comparison between propranolol 2% cream versus timolol 0.5% gel for the treatment of Kaposi sarcoma

Giorgio, Caterina M.; Licata, Gaetano; Briatico, Giulia; Babino, Graziella; Fulgione, Elisabetta; Gambardella, Alessio; Alfano, Roberto; Argenziano, Giuseppe

doi:10.1111/ijd.15407

Cited by 4 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This drug blocks β1 and β2 adrenergic receptors showing response in other vascular tumors, such as kaposiform hemangioendothelioma, tufted angioma, or even angiosarcoma . Despite the fact that, to our knowledge, oral propranolol has not been used in treating KS yet, its positive outcomes following topical use reported in several cases of KS and could justify its potential role in this vascular tumor …”

Section: Discussionmentioning

confidence: 99%

“…Several topical treatments have been successfully used for local control of the cutaneous manifestations of KS with variable results (imiquimod, alitetrinoin, rapamycin, and diphencyprone, as well as topical and intralesional chemotherapy). 1 Recently, treatment with topical timolol and propranolol has shown clinical benefits in cutaneous classic KS 2,3 ; however, there are no data available about the systemic use of β-adrenergic recep-tor blockers in this tumor. In this article, we report the case of a man with classic KS that showed substantial improvement after treatment with oral propranolol.…”

Section: Treatment With Oral Propranolol For Refractory Classic Cutan...mentioning

confidence: 99%

“…4 Despite the fact that, to our knowledge, oral propranolol has not been used in treating KS yet, its positive outcomes following topical use reported in several cases of KS and could justify its potential role in this vascular tumor. 3 It has been estimated that 75% of KS lesions express β-adrenergic receptors. 5 Furthermore, in vitro studies have demonstrated propranolol activity inducing HHV-8 lytic viral gene expression and noted a decrease of proliferation of endothelial cells transformed by HHV-8.…”

Section: Report Of a Case | A Mediterranean Hiv-negative Man In His 6...mentioning

confidence: 99%

“…In the phase 1 and 2 trials of LT, peripheral edema was reported in 20.0% to 31.7% of patients. 3,5 Often unresponsive to loop diuretics, spironolactone has been used. Cutaneous toxic effects observed in clinical trials were mostly grade 1 to 2 and included pruritus (12%), erythema (10%), maculopapular rash (5%), and pustular rash (1%), but grade 3 skin toxic effects did occur, including a grade 3 soft tissue infection.…”

mentioning

confidence: 99%

“…Cutaneous toxic effects observed in clinical trials were mostly grade 1 to 2 and included pruritus (12%), erythema (10%), maculopapular rash (5%), and pustular rash (1%), but grade 3 skin toxic effects did occur, including a grade 3 soft tissue infection. 3,5 Bullous dermatitis was not specifically described in these trials; however, it is included as a potential presentation of rash in the package insert for LT. 6 To our knowledge, no further information has been published regarding the characteristics of this eruption. These 2 cases suggest a novel association between LT and bullous dermatitis.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Treatment With Oral Propranolol For Refractory Classic Cutan...mentioning

confidence: 99%

Section: Report Of a Case | A Mediterranean Hiv-negative Man In His 6...mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma

et al. 2022

View full text Add to dashboard Cite

show abstract

HIV and the Skin

Bunker,

Piguet

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Within 2 years of defining acquired immune deficiency syndrome (AIDS) as a distinctive syndrome in 1981, human immunodeficiency virus (HIV) was identified as the causative agent. Dermatological involvement in AIDS has been appreciated since the disease was first recognised. Mucocutaneous involvement establishes criteria for diagnosis and staging; the prognostic significance of some complications, for example pruritic papular eruption/eosinophilic folliculitis, hairy leukoplakia and Kaposi sarcoma (KS), was well recognised before specific treatments were introduced. The proportion of patients with skin complications and the number of these manifestations in any one patient increase as HIV infection progresses and AIDS develops. The incidence and severity of several common cutaneous diseases (such as mollusca, herpes simplex and seborrhoeic dermatitis) are increased in patients with HIV and this correlates in many instances with the absolute numbers of CD4+ T cells. The effect HIV infection may have on some dermatological conditions such as psoriasis and leprosy is less clear‐cut. The advent of highly active combined antiretroviral therapy (ART) has been incalculably beneficial to patients with HIV, but novel side effects of these drugs (such as lipodystrophy) have emerged, and the skin can be affected by manifestations of the immune reconstitution inflammatory syndrome/immune reconstitution associated disease. The dermatological complications of HIV and AIDS may be distressing to patients and difficult for dermatologists to diagnose and manage. Also, many dermatoses presenting in the population at large need to be regarded as ‘indicator conditions’ to prompt advice about, and initiation of, HIV testing.

show abstract